And this is where targeted radiotherapeutics come in. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr ...

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies ...

Inizio brings in seasoned pharma exec for top job. A new chapter begins at Inizio with the appointment of Ryan Quigley as CEO ...

Inherited cardiac conditions (ICCs) can lead to heart failure, and fewer than half of all people diagnosed with heart failure ...

Lilly moved first. In January 2024, it launched LillyDirect, linking patients with telehealth providers and home delivery for its diabetes and weight-management portfolio. Pfizer followed in August ...

When everything comes together, pharma and biotech can do a great deal even if some of the data isn’t as strong, as long as ...

We’ve also seen investors lean into neurodegenerative and CNS conditions like schizophrenia. Karuna’s $14 billion acquisition ...

Both sales figures came in well ahead of analyst expectations and will heap pressure on Lilly's main rival in the GLP-1 ...

Thermo Fisher Scientific has agreed to acquire Clario Holdings for nearly $8.9 billion in cash, in a deal that would give it ...

Kennedy suggested the requirement for CES is one reason why the US is lagging behind other parts of the world in the rollout ...

That is a sizeable increase on Pfizer's September offer of $47.50 upfront and $22.50 in CVRs, which combined to give a deal ...

Prostate Cancer UK started a £42 million ($55 million), large-scale study called TRANSFORM last year to test that MRI-refined ...